Theragen Etex테라젠이텍스
066700 · KOSDAQ · ₩066700 · 테라젠이텍스
- Market cap
- ₩74B
- Enterprise value
- ₩75B
- P/E
- 28.2×
- P/B
- 0.6×
- Dividend yield
- 0.0%
- ROE
- 2.1%
- Net margin
- 1.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−41.8% from the high
₩1,845Today: ₩2,005 – ₩2,050₩3,470
Returns
- 1W0.0%
- 1M−10.0%
- 3M+1.8%
- 6M−33.6%
- YTD−36.1%
- 1Y−23.5%
- Volume today
- 26,238
- 0.4× the 20-day average
- Traded today
- ₩53M
- Listed shares
- 36,683,320
- EPS (12 months)
- ₩72
- Earnings yield 3.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 31 of 100 (50 is a normal day for this stock).
- MomentumFlat-4.7% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Theragen Etex stock overview
Theragen Etex (테라젠이텍스, KRX: 066700) is listed on KOSDAQ, in the Biotech & Pharma sector. The company manufactures and sells prescription and over-the-counter pharmaceuticals and operates a genomic analysis business offering DNA sequencing and RNA variant analysis services to hospitals, research institutes, and universities. Its shares closed at ₩2,020 on Oct 28, 2026, down 0.25% on the day, giving it a market value of ₩74B.
Key facts
- Market cap
- ₩74B
- Sector
- Biotech & Pharma
- Latest price change
- −0.25%
- As of
- Oct 28, 2026
- Main business
- The company manufactures and sells prescription and over-the-counter pharmaceuticals and operates a genomic analysis business offering DNA sequencing and RNA variant analysis services to hospitals, research institutes, and universities.
Quick answers about Theragen Etex
- What does Theragen Etex do?
- The company manufactures and sells prescription and over-the-counter pharmaceuticals and operates a genomic analysis business offering DNA sequencing and RNA variant analysis services to hospitals, research institutes, and universities. Through subsidiaries, it distributes prescription drugs and quasi-drugs, and a bio unit provides genome research and analysis services. It has also set up overseas entities in China and Hong Kong to expand its genomic analysis services into China.
- What is the market cap of Theragen Etex?
- The market capitalisation of Theragen Etex was ₩74B at the close on Oct 28, 2026.
- Who are the largest shareholders of Theragen Etex?
- According to the latest official filings, the largest reported holders are Ko Jae-hun (14.44%, as of Mar 19, 2026); Kim Seong-jin (3.62%, as of Mar 21, 2025); Ko Jin-eop (3.03%, as of Mar 21, 2025).
- When is the next earnings report from Theragen Etex?
- Korean companies rarely announce results dates in advance. Based on when Theragen Etex filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Theragen Etex?
- Yes. The National Pension Service held 0.40% of Theragen Etex shares as of Dec 31, 2018.
Company profile
The company manufactures and sells prescription and over-the-counter pharmaceuticals and operates a genomic analysis business offering DNA sequencing and RNA variant analysis services to hospitals, research institutes, and universities. Through subsidiaries, it distributes prescription drugs and quasi-drugs, and a bio unit provides genome research and analysis services. It has also set up overseas entities in China and Hong Kong to expand its genomic analysis services into China.
Written by AI from the company's latest annual report.
- Korean name
- 테라젠이텍스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 고진업, 박시홍
- Founded
- Sep 1990
- Listed
- May 2004
- Listed shares
- 36,683,320
- Fiscal year ends
- Month 12
- Website
- www.thera-gen.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Adjustment of Conversion PriceOct 19, 2026
- Insider shareholding reportOct 19, 2026
- Share cancellation decisionSep 29, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Adjustment of Conversion PriceJul 20, 2026
Titles in Korean until English translations are added.
Also known as: Theragen Etex / 테라젠이텍스 / 066700 / KRX:066700
Source: KRX statistical information